Relationship Between Glucocorticoids and Viral Load During the Omicron Wave in Mainland China

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2023 Nov 23

PMID 37993863

Authors

Guangxu Bai

Yan Li

Yang Liu

Xinming Wang

Xuezhong Yu

Lili Ren

Jun Xu

Affiliations

Soon will be listed here.

Abstract

Background: Coronavirus disease 19 (COVID-19) is a major public health problem that cannot be ignored. As a widely used drug in the treatment of COVID-19, whether glucocorticoids may accelerate the clearance of COVID-19 is still not clear, and the glucocorticoids may improve the prognosis of patients is also controversial. Therefore, to explore the relationship between COVID-19 viral load and the use of glucocorticoids we designed this study.

Methods: Patients with COVID-19 infection who were admitted to the emergency department of Peking Union Medical College Hospital from the end of 2022 to early 2023 were enrolled in this study. Characteristics of baseline, clinical and laboratory evaluation especially immunological indicator and daily viral load were carefully collected. Kolmogorov-Smirnov test, Student's t test, Mann-Whitney U test and proportional-hazards model (Cox model) were chosen as appropriate for comparison of variables.

Results: By comparing the daily COVID-19 viral load and prognosis of patients with and without glucocorticoid therapy, we found that glucocorticoids did not statistically enhance the clearance or replication of COVID-19, nor did it change the 28-days and in-hospital mortality. However, glucocorticoid therapy may be a favorable factor for COVID-19 negative conversion in Cox model. The inflammatory factors in patients with glucocorticoid therapy were significantly decreased.

Conclusions: We believe that the real effect of glucocorticoids may be to improve the destruction of host immune system caused by inflammatory storm through host immune regulation and then achieve the improvement of clinical symptoms.

References

Lee N, Chan K, Hui D, Ng E, Wu A, Chiu R . Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31(4):304-9. PMC: 7108318. DOI: 10.1016/j.jcv.2004.07.006. View

Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J . The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020; 81(1):e13-e20. PMC: 7195158. DOI: 10.1016/j.jinf.2020.03.062. View

Wang G, Li N, Wu Y, Xie G, Lin J, Huang C . [The COX regression analysis on the use of corticosteroids in the treatment of SARS]. Zhonghua Yi Xue Za Zhi. 2004; 84(13):1073-8. View

Knaus W, Draper E, Wagner D, Zimmerman J . APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10):818-29. View

Lawler P, Derde L, van de Veerdonk F, McVerry B, Huang D, Berry L . Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA. 2023; 329(14):1183-1196. PMC: 10326520. DOI: 10.1001/jama.2023.4480. View

Jain S, Kamimoto L, Bramley A, Schmitz A, Benoit S, Louie J . Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009; 361(20):1935-44. DOI: 10.1056/NEJMoa0906695. View

Kino T, Burd I, Segars J . Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels?. Int J Mol Sci. 2021; 22(13). PMC: 8269070. DOI: 10.3390/ijms22136764. View

Vincent J, Moreno R, Takala J, Willatts S, de Mendonca A, Bruining H . The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22(7):707-10. DOI: 10.1007/BF01709751. View

Cruz-Topete D, Cidlowski J . One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation. 2014; 22(1-2):20-32. PMC: 4243162. DOI: 10.1159/000362724. View

10.

Bouadma L, Mekontso-Dessap A, Burdet C, Merdji H, Poissy J, Dupuis C . High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial. JAMA Intern Med. 2022; 182(9):906-916. PMC: 9449796. DOI: 10.1001/jamainternmed.2022.2168. View

11.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

12.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

13.

Moreno G, Rodriguez A, Reyes L, Gomez J, Sole-Violan J, Diaz E . Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 2018; 44(9):1470-1482. PMC: 7095489. DOI: 10.1007/s00134-018-5332-4. View

14.

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

15.

Rafiullah M, Siddiqui K . Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. J Comp Eff Res. 2020; 9(18):1247-1254. PMC: 7694443. DOI: 10.2217/cer-2020-0146. View

16.

Dadras O, Afsahi A, Pashaei Z, Mojdeganlou H, Karimi A, Habibi P . The relationship between COVID-19 viral load and disease severity: A systematic review. Immun Inflamm Dis. 2021; 10(3):e580. PMC: 8926507. DOI: 10.1002/iid3.580. View

17.

Chien Y, Su C, Tsai H, Huang A, Lien C, Hung M . Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 influenza in Taiwan. J Infect. 2009; 60(2):168-74. DOI: 10.1016/j.jinf.2009.12.012. View

18.

Auyeung T, Lee J, Lai W, Choi C, Lee H, Lee J . The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005; 51(2):98-102. PMC: 7132384. DOI: 10.1016/j.jinf.2004.09.008. View

19.

Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Ac Siemieniuk R . A living WHO guideline on drugs for covid-19. BMJ. 2020; 370:m3379. DOI: 10.1136/bmj.m3379. View

20.

Han K, Ma H, An X, Su Y, Chen J, Lian Z . Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011; 53(4):326-33. DOI: 10.1093/cid/cir398. View